# US 2021/0063391 A1 · Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0063391 A1
- Document ID: US20210063391A1
- Status: Published application
- Kind: A1
- Application number: 17/046,195
- Filed: 2019-04-08
- Published: 2021-03-04
- Earliest claimed: 2018-04-09
- Applicants: The Regents of the University of Michigan
- Inventors: Sascha Gooneswardena; Rahul Rattan; Robert S. Rosenson
- Web page: https://patentgrep.com/patent/US20210063391A1

## CPC

- G01N 33/561: Immunoelectrophoresis
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to the use of microfluidic devices and systems to generate dynamic molecular signatures based on the detection of various biocellular markers. In particular, the present disclosure involves generating a dynamic molecular signature or profile using the cells of a subject (e.g., circulating monocytes), for various diagnostic and prognostic purposes, such as characterizing a disease or non-disease state, or predicting drug responsiveness. The microfluidic systems and methods of the present disclosure can be used to rapidly assess a plurality of clinical characteristics, which will ultimately enhance therapeutic efficacy and facilitate disease risk stratification.

## Claims

### Claim 1

A method of generating a dynamic molecular signature, the method comprising:
(a) performing an assay on a sample from a subject to detect at least one biocellular marker; and
(b) generating a dynamic molecular signature based on the detection of the at least one biocellular marker from the subject;
wherein the subject has been administered, or is being administered, at least one therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the assay is performed using a microfluidic immunoblotting device comprising a flat membrane-contacting surface and a plurality of non-connected parallel microfluidic channels, wherein the entire length of the microfluidic channels are open to the membrane-contacting surface.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the assay is performed by:
(a) transferring proteins from a sample onto a membrane;
(b) placing a membrane-contacting face of a microfluidic immunoblotting device onto the membrane;
(c) injecting an activating buffer into microfluidic channels of the device;
(d) injecting primary antibody solutions into the microfluidic channels of the device;
(e) detecting binding of antibodies with the antibody solutions to the proteins.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1 to 3, wherein the assay comprises selecting and isolating a group of cells from the sample prior to generating the dynamic molecular signature.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1 to 4, wherein the method further comprises assessing one or more effects of the therapeutic agent on gene or protein expression or activation.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1 to 5, wherein generating a dynamic molecular signature comprises quantifying a level of expression or activation of the at least one biocellular marker in the sample from the subject with reference to a control sample.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1 to 6, wherein the method further comprises correlating the dynamic molecular signature to one or more results of a clinical assessment of the subject.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1 to 7, wherein the therapeutic agent is evolocumab, and wherein the dynamic molecular signature represents effects of PCSK9 inhibition on the biocellular markers.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1 to 8, wherein the at least one biocellular marker comprises a protein involved in MAPK, NFkB, Akt, AMPK, mTOR, Jak-STAT, and PKA signaling pathways.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1 to 9, wherein the at least one biocellular marker comprises at least one of VCAM-1, ICAM-1, LOX-1, MCP-1 and MIP-1α.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1 to 10, wherein the at least one biocellular marker comprises at least one protein expressed by a peripheral blood mononuclear cell.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any of claims 1 to 11, wherein the at least one biocellular marker comprises at least one protein expressed by a circulating monocyte.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any of claims 1 to 12, wherein the method further comprises treating the subject with a therapeutic agent based on the dynamic molecular signature.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any of claims 1 to 13, wherein the method further comprises altering an aspect of the treatment based on the dynamic molecular signature.

### Claim 15

A method of assessing an effect of a therapeutic agent, the method comprising:
(a) performing an assay on a sample from a subject to detect at least one biocellular marker; and
(b) generating a dynamic molecular signature based on the detection of the at least one biocellular marker from the subject;
wherein the subject has been administered, or is being administered, at least one therapeutic agent.

### Claim 16

A dynamic molecular signature generated from a biological sample from a subject, wherein the signature comprises a detectable level of at least one biocellular marker from the subject across different timepoints or treatment regimens.

### Claim 17 (depends on 16)

The molecular signature of claim 16, wherein the at least one biocellular marker comprises a protein involved in MAPK, NFkB, Akt, AMPK, mTOR, Jak-STAT, and PKA signaling pathways.

### Claim 18 (depends on 16)

The molecular signature of claim 16, wherein the at least one biocellular marker comprises at least one of VCAM-1, ICAM-1, LOX-1, MCP-1 and MIP-1α.

### Claim 19 (depends on 16, 17, 18)

The molecular signature of any of claims 16 to 18, wherein the at least one biocellular marker comprises at least one protein expressed by a peripheral blood mononuclear cell.

### Claim 20 (depends on 16, 17, 18, 19)

The molecular signature of any of claims 16 to 19, wherein the at least one biocellular marker comprises at least one protein expressed by a circulating monocyte.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The molecular signature of any of claims 16 to 20, wherein the detectable level of the at least one biocellular marker comprises altered expression or activation of the at least one biocellular marker in the sample from the subject with reference to a control sample.
